Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1996;94:2285-2296

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eichhorn, E. J.
Right arrow Articles by Bristow, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eichhorn, E. J.
Right arrow Articles by Bristow, M. R.

(Circulation. 1996;94:2285-2296.)
© 1996 American Heart Association, Inc.


Articles

Medical Therapy Can Improve the Biological Properties of the Chronically Failing Heart

A New Era in the Treatment of Heart Failure

Eric J. Eichhorn, MD; Michael R. Bristow, MD, PhD

the Department of Internal Medicine (Cardiology Division) (E.J.E.), The University of Texas Southwestern and Dallas VA Medical Centers; and the Division of Cardiology (M.R.B.), University of Colorado Health Science Center (Denver).

Abstract Myocardial failure has been considered to be an irreversible and progressive process characterized by ventricular enlargement, chamber geometric alterations, and diminished pump performance. However, more recent evidence has suggested that certain types of medical therapy may lead to retardation and even reversal of the cardiomyopathic process. In the failing heart, long-term neurohormonal/autocrine-paracrine activation results in abnormalities in myocyte growth, energy production and utilization, calcium flux, and receptor regulation that produce a progressively dysfunctional, mechanically inefficient heart. Interventions such as ACE inhibition and ß-blockade result in a reduction in the harmful long-term consequences of neurohormonal/autocrine-paracrine effects and retard the progression of left ventricular dysfunction or ventricular remodeling. Furthermore, in subjects with idiopathic dilated or ischemic cardiomyopathy, antiadrenergic therapy with ß-blocking agents appears to be able to partially reverse systolic dysfunction and ventricular remodeling. Although the precise mechanisms underlying this latter effect have not yet been elucidated, the general mechanism appears to be via improvement in the biological function of the cardiac myocyte. Such an improvement in the intrinsic defect(s) responsible for myocardial failure will likely translate into important clinical benefits.


Key Words: heart failure • remodeling • myocardial contraction




This article has been cited by other articles:


Home page
ANGIOLOGYHome page
S. H. Oh and D. G. Meyers
Afterload Reduction May Halt and Beta-Adrenergic Blockade May Worsen Progression of Left Ventricular Dysfunction in Patients With Chronic Compensated Mitral Regurgitation: A Retrospective Cohort Study
Angiology, April 1, 2007; 58(2): 196 - 202.
[Abstract] [PDF]


Home page
CirculationHome page
P. Knaapen, T. Germans, J. Knuuti, W. J. Paulus, P. A. Dijkmans, C. P. Allaart, A. A. Lammertsma, and F. C. Visser
Myocardial Energetics and Efficiency: Current Status of the Noninvasive Approach
Circulation, February 20, 2007; 115(7): 918 - 927.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. C. Sucharov, P. D. Mariner, K. R. Nunley, C. Long, L. Leinwand, and M. R. Bristow
A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction
Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1299 - H1308.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
A. Barsheshet, M. Garty, E. Grossman, A. Sandach, B. S. Lewis, S. Gottlieb, A. Shotan, S. Behar, A. Caspi, R. Schwartz, et al.
Admission Blood Glucose Level and Mortality Among Hospitalized Nondiabetic Patients With Heart Failure.
Arch Intern Med, August 14, 2006; 166(15): 1613 - 1619.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Shigeyama, Y. Yasumura, A. Sakamoto, Y. Ishida, T. Fukutomi, M. Itoh, K. Miyatake, and M. Kitakaze
Increased gene expression of collagen Types I and III is inhibited by {beta}-receptor blockade in patients with dilated cardiomyopathy
Eur. Heart J., December 2, 2005; 26(24): 2698 - 2705.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. R. Goldsmith and M. Gheorghiade
Vasopressin Antagonism in Heart Failure
J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1785 - 1791.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
R. G. Dean, L. C. Balding, R. Candido, W. C. Burns, Z. Cao, S. M. Twigg, and L. M. Burrell
Connective Tissue Growth Factor and Cardiac Fibrosis after Myocardial Infarction
J. Histochem. Cytochem., October 1, 2005; 53(10): 1245 - 1256.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Kiriazis, X.-J. Du, X. Feng, E. Hotchkin, T. Marshall, S. Finch, X.-M. Gao, G. Lambert, J. K. Choate, and D. M. Kaye
Preserved left ventricular structure and function in mice with cardiac sympathetic hyperinnervation
Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1359 - H1365.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. W. Siecke and P. A. Insel
Clarifying the effects of adrenergic receptor polymorphisms by measuring synaptic parameters
J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2016 - 2018.
[Full Text] [PDF]


Home page
Am J Crit CareHome page
S. K. Hamlin, P. S. Villars, J. T. Kanusky, and A. D. Shaw
Role of Diastole in Left Ventricular Function, II: Diagnosis and Treatment
Am. J. Crit. Care., November 1, 2004; 13(6): 453 - 466.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
D. S Roffman
High-Versus Low-Dose ACE Inhibitor Therapy in Chronic Heart Failure
Ann. Pharmacother., May 1, 2004; 38(5): 831 - 838.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J. L. Bauman and R. L. Talbert
Pharmacodynamics of{beta}-Blockers in Heart Failure: Lessons from the Carvedilol Or Metoprolol European Trial
Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2004; 9(2): 117 - 128.
[Abstract] [PDF]


Home page
Clin. DiabetesHome page
D. S.H. Bell
Heart Failure: A Serious and Common Comorbidity of Diabetes
Clin. Diabetes, April 1, 2004; 22(2): 61 - 65.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K. Fukuchi, Y. Yasumura, K. Kiso, K. Hayashida, K. Miyatake, and Y. Ishida
Gated Myocardial SPECT to Predict Response to {beta}-Blocker Therapy in Patients with Idiopathic Dilated Cardiomyopathy
J. Nucl. Med., April 1, 2004; 45(4): 527 - 531.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. J. Eichhorn, P. A. Grayburn, S. A. Mayer, M. St John Sutton, C. Appleton, J. Plehn, J. Oh, B. Greenberg, A. DeMaria, R. Frantz, et al.
Myocardial Contractile Reserve by Dobutamine Stress Echocardiography Predicts Improvement in Ejection Fraction With {beta}-Blockade in Patients With Heart Failure: The {beta}-Blocker Evaluation of Survival Trial (BEST)
Circulation, November 11, 2003; 108(19): 2336 - 2341.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. C. Arora, R. Cardinal, F. M. Smith, J. L. Ardell, L. J. Dell'Italia, and J. A. Armour
Intrinsic cardiac nervous system in tachycardia induced heart failure
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R1212 - R1223.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. Bello, D. J. Shah, G. M. Farah, S. Di Luzio, M. Parker, M. R. Johnson, W. G. Cotts, F. J. Klocke, R. O. Bonow, R. M. Judd, et al.
Gadolinium Cardiovascular Magnetic Resonance Predicts Reversible Myocardial Dysfunction and Remodeling in Patients With Heart Failure Undergoing {beta}-Blocker Therapy
Circulation, October 21, 2003; 108(16): 1945 - 1953.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R.-P. Xiao, S.-J. Zhang, K. Chakir, P. Avdonin, W. Zhu, R. A. Bond, C. W. Balke, E. G. Lakatta, and H. Cheng
Enhanced Gi Signaling Selectively Negates {beta}2-Adrenergic Receptor (AR)- but Not {beta}1-AR-Mediated Positive Inotropic Effect in Myocytes From Failing Rat Hearts
Circulation, September 30, 2003; 108(13): 1633 - 1639.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
D. S.H. Bell
Heart Failure: The frequent, forgotten, and often fatal complication of diabetes
Diabetes Care, August 1, 2003; 26(8): 2433 - 2441.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. B. Adamson, K. J. Kleckner, W. L. VanHout, S. Srinivasan, and W. T. Abraham
Cardiac Resynchronization Therapy Improves Heart Rate Variability in Patients with Symptomatic Heart Failure
Circulation, July 22, 2003; 108(3): 266 - 269.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. H. Au, E. M. Udris, V. S. Fan, J. R. Curtis, M. B. McDonell, and S. D. Fihn
Risk of Mortality and Heart Failure Exacerbations Associated With Inhaled {beta}-Adrenoceptor Agonists Among Patients With Known Left Ventricular Systolic Dysfunction
Chest, June 1, 2003; 123(6): 1964 - 1969.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. Jessup and S. Brozena
Heart Failure
N. Engl. J. Med., May 15, 2003; 348(20): 2007 - 2018.
[Full Text] [PDF]


Home page
NEJMHome page
B. D. Lowes, E. M. Gilbert, W. T. Abraham, W. A. Minobe, P. Larrabee, D. Ferguson, E. E. Wolfel, J. Lindenfeld, T. Tsvetkova, A. D. Robertson, et al.
Myocardial Gene Expression in Dilated Cardiomyopathy Treated with Beta-Blocking Agents
N. Engl. J. Med., May 2, 2002; 346(18): 1357 - 1365.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Naitoh, J. Risvanis, L. C. Balding, C. I. Johnston, and L. M. Burrell
Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition
Cardiovasc Res, April 1, 2002; 54(1): 51 - 57.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. M. Massie
Neurohormonal blockade in chronic heart failure: How much is enough? can there be too much?
J. Am. Coll. Cardiol., January 2, 2002; 39(1): 79 - 82.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
P. M. L. Janssen, G. Hasenfuss, O. Zeitz, S. E. Lehnart, J. Prestle, D. Darmer, J. Holtz, and H. Schumann
Load-dependent induction of apoptosis in multicellular myocardial preparations
Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H349 - H356.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. E. Udelson, W. B. Smith, G. H. Hendrix, C. A. Painchaud, M. Ghazzi, I. Thomas, J. K. Ghali, P. Selaru, F. Chanoine, M. L. Pressler, et al.
Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure
Circulation, November 13, 2001; 104(20): 2417 - 2423.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
R.-P. Xiao
{beta}-Adrenergic Signaling in the Heart: Dual Coupling of the {beta}2-Adrenergic Receptor to Gs and Gi Proteins
Sci. Signal., October 16, 2001; 2001(104): re15 - re15.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. J. Herron, F. S. Korte, and K. S. McDonald
Loaded shortening and power output in cardiac myocytes are dependent on myosin heavy chain isoform expression
Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1217 - H1222.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
S. Kaab and M. Nabauer
Diversity of ion channel expression in health and disease
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K31 - K40.
[Abstract] [PDF]


Home page
CirculationHome page
H. Kubo, K. B. Margulies, V. Piacentino III, J. P. Gaughan, and S. R. Houser
Patients With End-Stage Congestive Heart Failure Treated With {beta}-Adrenergic Receptor Antagonists Have Improved Ventricular Myocyte Calcium Regulatory Protein Abundance
Circulation, August 28, 2001; 104(9): 1012 - 1018.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
H.P Brunner-La Rocca, M.D Esler, G.L Jennings, and D.M Kaye
Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure
Eur. Heart J., July 1, 2001; 22(13): 1136 - 1143.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Kline, T. Jiang, X. Xu, V. O. Rybin, and S. F. Steinberg
Abnormal calcium and protein kinase C-{epsilon} signaling in hypertrophied atrial tumor myocytes (AT-1 cells)
Am J Physiol Heart Circ Physiol, June 1, 2001; 280(6): H2761 - H2769.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. P. Brunner-La Rocca, D. M. Kaye, R. L. Woods, J. Hastings, and M. D. Esler
Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects
J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1221 - 1227.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. A. Gaballa, A. Eckhart, W. J. Koch, and S. Goldman
Vascular {beta}-adrenergic receptor system is dysfunctional after myocardial infarction
Am J Physiol Heart Circ Physiol, March 1, 2001; 280(3): H1129 - H1135.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
W.-Z. Zhu, M. Zheng, W. J. Koch, R. J. Lefkowitz, B. K. Kobilka, and R.-P. Xiao
Dual modulation of cell survival and cell death by beta 2-adrenergic signaling in adult mouse cardiac myocytes
PNAS, February 13, 2001; 98(4): 1607 - 1612.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. R. Bristow
Of Phospholamban, Mice, and Humans With Heart Failure
Circulation, February 13, 2001; 103(6): 787 - 788.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
M. Gomberg-Maitland, D. A. Baran, and V. Fuster
Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist
Arch Intern Med, February 12, 2001; 161(3): 342 - 352.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Wada, K. Saito, T. Kanda, I. Kobayashi, H. Fujii, S. Fujigaki, N. Maekawa, H. Takatsu, H. Fujiwara, K. Sekikawa, et al.
Tumor Necrosis Factor-{{alpha}} (TNF-{{alpha}}) Plays a Protective Role in Acute Viral Myocarditis in Mice : A Study Using Mice Lacking TNF-{{alpha}}
Circulation, February 6, 2001; 103(5): 743 - 749.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Cice, L. Ferrara, A. Di Benedetto, P. E. Russo, G. Marinelli, F. Pavese, and A. Iacono
Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial
J. Am. Coll. Cardiol., February 1, 2001; 37(2): 407 - 411.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
A. P. Maggioni
HEART FAILURE: Treatment strategies for heart failure: {beta} blockers and antiarrhythmics
Heart, January 1, 2001; 85(1): 97 - 103.
[Full Text]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Freeman, C. Colon-Rivera, M. C. Olsson, R. L. Moore, H. D. Weinberger, I. L. Grupp, K. L. Vikstrom, G. Iaccarino, W. J. Koch, and L. A. Leinwand
Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene
Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H151 - H159.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. F. Steinberg
The Cellular Actions of {beta}-Adrenergic Receptor Agonists : Looking Beyond cAMP
Circ. Res., December 8, 2000; 87(12): 1079 - 1082.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Pons-Llado, M. Ballester, X. Borras, F. Carreras, I. Carrio, J. Lopez-Contreras, A. Roca-Cusachs, J. Marrugat, and J. Narula
Myocardial cell damage in human hypertension
J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2198 - 2203.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. M. Burrell, N. K. Farina, L. C. Balding, and C. I. Johnston
Beneficial Renal and Cardiac Effects of Vasopeptidase Inhibition With S21402 in Heart Failure
Hypertension, December 1, 2000; 36(6): 1105 - 1111.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
E. A.K. Beyer, D. M. McMullan, R. Delgado, I. Gregoric, B. Radovancevic, and O.H. Frazier
Normalization of native heart function years after heterotopic transplantation
Ann. Thorac. Surg., November 1, 2000; 70(5): 1690 - 1691.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Y.-Y. Zhou, D. Yang, W.-Z. Zhu, S.-J. Zhang, D.-J. Wang, D. K. Rohrer, E. Devic, B. K. Kobilka, E. G. Lakatta, H. Cheng, et al.
Spontaneous Activation of beta 2- but Not beta 1-Adrenoceptors Expressed in Cardiac Myocytes from beta 1beta 2 Double Knockout Mice
Mol. Pharmacol., November 1, 2000; 58(5): 887 - 894.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Nagata, C. Communal, C. C. Lim, M. Jain, T. M. Suter, F. R. Eberli, N. Satoh, W. S. Colucci, C. S. Apstein, and R. Liao
Altered beta -adrenergic signal transduction in nonfailing hypertrophied myocytes from Dahl salt-sensitive rats
Am J Physiol Heart Circ Physiol, November 1, 2000; 279(5): H2502 - H2508.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. S. B. Beanlands, C. Nahmias, E. Gordon, G. Coates, R. deKemp, G. Firnau, and E. Fallen
The Effects of {beta}1-Blockade on Oxidative Metabolism and the Metabolic Cost of Ventricular Work in Patients With Left Ventricular Dysfunction : A Double-Blind, Placebo-Controlled, Positron-Emission Tomography Study
Circulation, October 24, 2000; 102(17): 2070 - 2075.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R.-P. Xiao
Cell Logic for Dual Coupling of a Single Class of Receptors to Gs and Gi Proteins
Circ. Res., October 13, 2000; 87(8): 635 - 637.
[Full Text] [PDF]


Home page
Eur Heart JHome page
G. Cice, E. Tagliamonte, L. Ferrara, and A. Iacono
Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study
Eur. Heart J., August 1, 2000; 21(15): 1259 - 1264.
[Abstract] [PDF]


Home page
CirculationHome page
M. R. Bristow
What Type of {beta}-Blocker Should Be Used to Treat Chronic Heart Failure?
Circulation, August 1, 2000; 102(5): 484 - 486.
[Full Text] [PDF]


Home page
CirculationHome page
T. Tamura, S. Said, J. Harris, W. Lu, and A. M. Gerdes
Reverse Remodeling of Cardiac Myocyte Hypertrophy in Hypertension and Failure by Targeting of the Renin-Angiotensin System
Circulation, July 11, 2000; 102(2): 253 - 259.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. R. Bristow
{beta}-Adrenergic Receptor Blockade in Chronic Heart Failure
Circulation, February 8, 2000; 101(5): 558 - 569.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. S. Westheim, P. Bostrom, C. C. Christensen, H. Parikka, E. O. Rykke, and L. Toivonen
Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure
J. Am. Coll. Cardiol., November 15, 1999; 34(6): 1794 - 1801.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. H. Dunlap, C. A. Sueta, L. Tomasko, and K. F. Adams Jr.
Association of body mass, gender and race with heart failure primarily due to hypertension
J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1602 - 1608.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. L. Mann
Mechanisms and Models in Heart Failure : A Combinatorial Approach
Circulation, August 31, 1999; 100(9): 999 - 1008.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M.-C. Cho, A. Rapacciuolo, W. J. Koch, Y. Kobayashi, L. R. Jones, and H. A. Rockman
Defective beta -Adrenergic Receptor Signaling Precedes the Development of Dilated Cardiomyopathy in Transgenic Mice with Calsequestrin Overexpression
J. Biol. Chem., August 6, 1999; 274(32): 22251 - 22256.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
P. Schaffer, B. Pelzmann, E. Bernhart, P. Lang, H. Machler, B. Rigler, and B. Koidl